FDA Envisions Flexible Approach To Expanded Use Of Accelerated Approval

FDA’s new guidance on expedited drug development and review programs stresses agency flexibility in determining when an “unmet medical need” exists and when there is sufficient evidence for awarding accelerated approval.

The draft guidance expands the definition of unmet need and suggests FDA will consider a host of potential advantages that an investigational drug has over available therapies in deciding whether...